An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder
Phase: PHASE3 | Sponsor: Cybin IRL Limited | Compound: Psychedelic
- Status
- recruiting
- Institution
- Cybin IRL Limited
- Start date
- 2025-11-30
- End date
- 2027-05-08
- Registry ID
- NCT06793397
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.